download
print
% Change:
Volume:
52-Week High:
52-Week Low:

EVENTS & PRESENTATIONS

Piper Sandler 36th Annual Healthcare Conference

Past Events ›

Jefferies London Healthcare Conference

Past Events ›

UBS Global Healthcare Conference

Past Events ›

View all events and presentations ›
container-970 d-flex flex-1

2023 Annual Report

Download

2023 Corporate Responsibility Report

Download

capella

Investor & Scientific Presentations

Explore Capella ›

Investor Toolkit

Quarterly Earnings Presentation - Icon

Q3 2024 Earnings Presentation VIEW PDF ›

10-K - Icon

Latest Form 10-K VIEW PDF ›

10-Q - Icon

Latest Form10-Q VIEW PDF ›

sec-icon

SEC
Filings VIEW All ›

sec-icon

2024 Proxy
Statement LEARN MORE ›

View all resources and documents ›

Discover Our Commitment to Patients, Employees, and Our Communities

Corporate Responsibility ›

PRESS RELEASES

Alnylam to Webcast Presentation at Piper Sandler 36th Annual Healthcare Conference

Learn More ›

Alnylam Announces U.S. Food and Drug Administration Acceptance of Supplemental New Drug Application for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy

Learn More ›

Alnylam Announces Interim Phase 1 Data of Nucresiran (ALN-TTRsc04) Showing Rapid Knockdown of TTR that is Sustained at Six Months Following a Single Dose

Learn More ›

View all press releases ›